Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity
- PMID: 36875908
- PMCID: PMC9982292
- DOI: 10.1016/j.jaccao.2022.11.001
Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity
Keywords: European Society of Cardiology; cardio-oncology; cardiovascular disease; clinical practice guidelines.
Conflict of interest statement
This study was supported in part by a Japan Society for the Promotion of Science/Ministry of Education, Culture, Sports, Science and Technology (KAKENHI 18K12134 and 20K08427); the Ministry of Health, Labour and Welfare (20FA1018 and 20KC2009); and the Agency for Medical Research and Development (20ck0106633h0001) for Dr. Sase. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
References
-
- Lyon A.R., Lopez-Fernandez T., Couch L.S., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 2022;43(41):4229–4361. - PubMed
-
- Zamorano J.L., Lancellotti P., Rodriguez Munoz D., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37(36):2768–2801. - PubMed
-
- Shelburne N., Simonds N.I., Adhikari B., et al. Changing hearts and minds: improving outcomes in cancer treatment-related cardiotoxicity. Curr Oncol Rep. 2019;21(1):9. - PubMed
-
- Levis B.E., Binkley P.F., Shapiro C.L. Cardiotoxic effects of anthracycline-based therapy: what is the evidence, and what are the potential harms? Lancet Oncol. 2017;18(8):e445–e456. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
